Cogstate (ASX.CGS) is pleased to announce the appointment of Ms Kim Wenn as an Independent Non-Executive Director, effective immediately.
Kim brings extensive technology experience and strong commercial expertise to the Board of Cogstate, with over 30 years experience in innovation roles. Until July 2018, Kim held the role of Chief Information Officer at Tabcorp Holdings, an ASX50 listed company where Kim led a team of 1,200 technology experts to drive strategic direction through digital transformation. Kim’s experience includes, among other things, business strategy, governance and change management—with a focus on digital disruption.
In addition to her role at Cogstate, Kim is a Non-Executive Director at Volt Bank.
“We are incredibly pleased to be able to announce that Kim will be joining the Board of Cogstate” commented Mr Martyn Myer AO, Chairman of Cogstate Limited. “Kim’s addition to the Board adds valuable technology expertise and further broadens the commercial experience of the Cogstate Board. Kim’s experience in highly regulated sectors outside of the healthcare industry will bring a unique perspective to inform our innovation strategy. Kim is extremely excited about the role that Cogstate can play in improving brain health through delivery of technology solutions.”
Kim holds a Bachelor of Computer Science from Monash University and completed an Advanced Management Program from Harvard University. She is a graduate member of the Australian Institute of Company Directors.
This announcement was authorised for release by the Board of Directors of Cogstate Ltd.
Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerized cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. Cogstate and pharmaceutical company, Eisai, recently established a global exclusive partnership to develop and market cognitive assessment tools for individuals and doctors around the world.